Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)
Status:
Not yet recruiting
Trial end date:
2020-11-22
Target enrollment:
Participant gender:
Summary
This study is a prospective, phase II, multi-center, randomized, double-blind,
placebo-controlled trial to evaluate the efficacy and safety of mavrilimumab in hospitalized
patients with acute respiratory failure requiring oxygen supplementation in COVID- 19
pneumonia and a hyper-inflammatory status. The study will randomize patients to mavrilimumab
or placebo, in addition to standard of care per local practice. The total trial duration will
be 12 weeks after single mavrilimumab or placebo dose.